UNICREDIT BANK/CALL/AMGEN/450/0.1/18.06.25 | Real-time BOERSE MUENCHEN 12:41:51 22/05/2024 BST | ||
| 0.57 EUR | 0.00% |
|
| Current month | +235.29% | ||
| 1 month | +256.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 22/05/24 | 0.57 | 0.00% |
| 21/05/24 | 0.57 | 0.00% |
| 20/05/24 | 0.57 | 0.00% |
| 17/05/24 | 0.57 | -5.00% |
| 16/05/24 | 0.6 | -6.25% |
Real-time BOERSE MUENCHEN
Last update May 22, 2024 at 12:41 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD1QZ0 |
| ISIN | DE000HD1QZ04 |
| Date issued | 08/01/2024 |
| Strike | 450 $ |
| Maturity | 18/06/2025 (392 Days) |
| Parity | 10 : 1 |
| Emission price | 0.6 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.82 € |
|---|---|
| Lowest since issue | 0.033 € |
| Spread | 0.05 € |
| Spread % | 8.33% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
314.8
USD
Average target price
316.1
USD
Spread / Average Target
+0.39%
- Stock Market
- Warrants
- Warrant
